About Us
Our Science
Clinical Trials
News and Events
Contact
News and Events
Beacon Therapeutics launches with ยฃ96 million ($120 million) to develop a new generation of gene therapies for retinal diseases resulting in blindness
Subretinal Gene Therapy Drug AGTC-501 XLRP Phase 1/2 Multicenter Study (Horizon): 24-Month Interim Safety Results
